Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke. Novartis heart drug pelacarsen failed final study. Drug lowered Lp(a) but not heart attacks/strokes. Second trial disappointment for Novartis in a week.